BiotechTube

HRS -8427 + Imipenem and Cilastatin Sodium

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Conditions

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Trial Timeline

Dec 1, 2023 → Jul 1, 2024

NCT ID
NCT06144060

About HRS -8427 + Imipenem and Cilastatin Sodium

HRS -8427 + Imipenem and Cilastatin Sodium is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP). The current trial status is unknown. This product is registered under clinical trial identifier NCT06144060. Target conditions include Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP).

What happened to similar drugs?

18 of 20 similar drugs in Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) were approved

Approved (18) Terminated (1) Active (2)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06144060Phase 2UNKNOWN

Competing Products

20 competing products in Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29